Davos Alzheimer's Collaborative

Healthcare system preparedness: dac is investing to transform the way healthcare systems worldwide detect, diagnose and treat alzheimer's. The goal is to take advantage of future innovations to improve the quality of life for people everywhere. In 2023, dac continued to advance 7 flagship projects in 6 countries as well as support and monitor the execution of the initial grants program (12 grants in total). Additionally, dac designed our next set of flagship projects and has been working closely with sites across the globe to launch the program in 2024.

Global clinical trials - dac is maintaining a network of more than 30 european sites organized for accelerating studies and implementing novel trial designs that is being funded by a pharmaceutical company sponsor. Dac's work through the global cohort development program should be able to provide clinical trial ready populations in 2024 and create more opportunities for the global clinical trial program.

Global cohorts - dac is building global cohorts to advance understanding of Alzheimer's among diverse populations. This data will provide the foundation for identifying new biomarkers and developing targeted treatments that work for people worldwide. In 2023, dac advanced our research agenda by:- providing multi-year funding to worldwide fingers to adapt and customize their risk reduction protocol in over 60 countries.- completing the first two phases of a long-term partnership with aga khan university in nairobi, kenya that is validating cognitive tests, saliva based polygenic risk scores and novel digital cognitive assessments in local east african population with the goal of creating a clinical trial ready cohort for testing pharmacological and non-pharmacological interventions. - acquiring blood samples from first 300 of a 3000 person highly characterized (pet, clinical dx) south korean cohort and access to 1,000 blood samples from a long-standing cohort in the latam/caribbean region for further analysis by dac's network of diagnostic and pharma partners to generate ad blood biomarker validation data.- building and maintaining a robust pipeline of committed cohorts with detailed proposals mous, ranging from colombia to tanzania to rural Texas, to test and validate early cognitive impairment detection technologies with a focus on remote, underserved areas to find tools that can more easily scale globally.